Singapore Clinical Trial: A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as the safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the effi... Read More

Singapore Clinical Trial: A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as the safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the effi... Read More

Singapore Clinical Trial: A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab A... Read More

Singapore Clinical Trial: A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants with Type 2 Diabetes Mellitus and Participants with Overweight or Obesity without Type 2 Diabetes Mellitus.

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Ret... Read More

Singapore Clinical Trial: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination Wi... Read More

Singapore Clinical Trial: EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate ... Read More

Financially Strong Stock to Buy Now for an Upside of 40%; Are You Holding It?

India, April 6 -- This article outlines HSBC's bullish view on ITC Hotels, highlighting a 40 percent upside. It discusses steady Q4 FY26 performance, robust domestic demand offsetting geopolitical cha... Read More

Union Bank of India rises as domestic advances grow 10% YoY in Q4 FY26

Mumbai, April 6 -- Domestic deposits grew 2.72% YoY to Rs 13,06,297 crore, while rising 6.88% QoQ as of 31 March 2026. Domestic CASA deposits stood at Rs 4,59,988 crore, increasing 7.90% YoY and 10.82... Read More

8 years on, construction on Narsingdi Hospital's new building remains incomplete

Dhaka, April 6 -- The construction of a new building for the 100-bed district hospital in Narsingdi has not been completed in eight years. Meanwhile, patient services are being disrupted due to lack o... Read More

Tata Group Stock Skyrockets 8% After Its Revenue Increases 20% YoY

India, April 6 -- This Tata Group retail player is in focus as its shares surged 8 percent in today's session, outperforming the broader market after reporting a strong Q4 business update. The rally c... Read More

• ««
• «
• 232
• 233
• 234
• 235
• 236
• 237
• 238
• 239
• 240
• 241
• »
• »»